The University of Chicago Header Logo

Koen Van Besien

TitlePROFESSOR
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01CA254035     (JIN, MOONSOO M)Apr 23, 2021 - Mar 31, 2026
    NIH
    CAR T Cells for Advanced Thyroid Cancer
    Role: Co-Principal Investigator
    K24CA116471     (VAN BESIEN, KOEN WALTER)Aug 10, 2007 - Jul 31, 2013
    NIH
    Immunologic and pharmacologic studies in allotransplant
    Role: Principal Investigator
    R21CA115097     (VAN BESIEN, KOEN WALTER)May 15, 2006 - Apr 30, 2009
    NIH
    Busulfan conditioning: optimization, kinetics, genomics
    Role: Principal Investigator
    R21CA101337     (VAN BESIEN, KOEN WALTER)Jun 12, 2003 - May 31, 2006
    NIH
    Minor Histocompatilibity Vaccination After Allo-Transpl*
    Role: Principal Investigator
    R21CA100240     (VAN BESIEN, KOEN WALTER)Apr 10, 2003 - Mar 31, 2006
    NIH
    TCR-gene modified t-cells for adaptive immunotherapy
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lin C, Patel AA, Huo D, Karrison T, Van Besien K, Godwin JE, Sher D, Weiner H, Green M, Wade JL, Klisovic R, Baer MR, Larson RA, Stock W, Odenike O, Lin C, Patel AA, Huo D, Karrison T, van Besien K, Godwin J, Sher D, Weiner H, Green M, Wade JL, Klisovic R, Baer MR, Larson RA, Stock W, Odenike O. A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 Nov 26; 8(22):5735-5743. PMID: 39250708.
      Citations: 4     Fields:    
    2. Daunov M, van Besien K. High-Dose Chemotherapy and Autologous or Allogeneic Transplantation in Aggressive B-Cell Lymphoma-Is There Still a Role? Cells. 2024 Oct 27; 13(21). PMID: 39513887; PMCID: PMC11545473.
      Citations:    
    3. Gyurkocza B, Nath R, Seropian S, Choe H, Litzow MR, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Hari P, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco JJ, Jamieson K, Silverman M, Van Besien K, Schuster M, Law AD, Larkin K, Pandit-Taskar N, Rowley SD, Munshi P, Cook R, Levy MY, Lazarus HM, Sandmaier BM, Pagel JM, Reddy V, MacDougall J, McNamara K, Spross J, Haeuber E, Vusirikala M, Nahar A, Desai A, Giralt S. Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. J Clin Oncol. 2024 Sep 19; JCO2302018. PMID: 39298738.
      Citations:    Fields:    
    4. Ghalehsari N, Castillo Tokumori F, Chen Z, Liu M, Mayer SA, Zeinah GA, Shore TB, Ritchie EK, Silver RT, Scandura JM, Roboz GJ, van Besien K, Gomez-Arteaga A. Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors). Transplant Cell Ther. 2024 Nov; 30(11):1100.e1-1100.e11. PMID: 39243817.
      Citations:    Fields:    
    5. van Besien K, Liu H, Margevicius S, Fu P, Artz A, Chaekal OK, Metheny L, Shore T, Kosuri S, Mayer S, Gomez-Arteaga A, Kwon M. Haplo-cord transplant. Realizing the potential of umbilical cord blood grafts. - A review of techniques and analysis of outcomes. Leuk Lymphoma. 2024 Oct; 65(10):1384-1397. PMID: 38949786.
      Citations:    Fields:    Translation:Humans
    6. Nikiforow S, Whangbo JS, Reshef R, Tsai DE, Bunin N, Abu-Arja R, Mahadeo KM, Weng WK, Van Besien K, Loeb D, Nasta SD, Nemecek ER, Zhao W, Sun Y, Galderisi F, Wahlstrom J, Mehta A, Gamelin L, Dinavahi R, Prockop S. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Adv. 2024 06 25; 8(12):3001-3012. PMID: 38625984; PMCID: PMC11215195.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    7. Hammond TC, Purbhoo MA, Kadel S, Ritz J, Nikiforow S, Daley H, Shaw K, van Besien K, Gomez-Arteaga A, Stevens D, Ortuzar W, Michelet X, Smith R, Moskowitz D, Masakayan R, Yigit B, Boi S, Soh KT, Chamberland J, Song X, Qin Y, Mishchenko I, Kirby M, Nasonenko V, Buffa A, Buell JS, Chand D, van Dijk M, Stebbing J, Exley MA. A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome. Nat Commun. 2024 Feb 06; 15(1):974. PMID: 38321023; PMCID: PMC10847411.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    8. Marullo R, Rutherford SC, Revuelta MV, Zamponi N, Culjkovic-Kraljacic B, Kotlov N, Di Siervi N, Lara-Garcia J, Allan JN, Ruan J, Furman RR, Chen Z, Shore TB, Phillips AA, Mayer S, Hsu J, van Besien K, Leonard JP, Borden KLB, Inghirami G, Martin P, Cerchietti L. XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells. Cancer Res. 2024 01 02; 84(1):101-117. PMID: 37801604; PMCID: PMC10758694.
      Citations: 3     Fields:    Translation:HumansCells
    9. Plate M, Jessurun J, van Besien K. Immune reconstitution inflammatory syndrome in a patient with M.haemophilum infection after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2023 12; 64(13):2214-2216. PMID: 37674433.
      Citations:    Fields:    Translation:Humans
    10. Sugita M, Yamazaki T, Alhomoud M, Latouche JB, Golden E, Boyer O, Van Besien K, Formenti SC, Galluzzi L, Guzman ML, Martinet J. Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia. Cell Death Dis. 2023 05 04; 14(5):305. PMID: 37142568; PMCID: PMC10160073.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    11. Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A, Sigouros M, van Besien K, Horwitz S, Rutherford SC, Mulvey E, Revuelta MV, Xiang J, Alonso A, Melnick A, Elemento O, Inghirami G, Leonard JP, Cerchietti L, Martin P. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023 05 04; 141(18):2194-2205. PMID: 36796016; PMCID: PMC10356559.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    12. Gomez-Arteaga A, Orfali N, Pasciolla M, Baptiste A, Guindine I, Hsu J, Lin J, Mayer SA, Phillips AA, Shore TB, Simonson PD, DiCarlo E, Yoon S, Muthukumar T, van Besien K. Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (ESKD). Bone Marrow Transplant. 2023 07; 58(7):835-838. PMID: 37045941.
      Citations:    Fields:    Translation:Humans
    13. Hsu J, Van Besien K, Glesby MJ, Pahwa S, Coletti A, Warshaw MG, Petz L, Moore TB, Chen YH, Pallikkuth S, Dhummakupt A, Cortado R, Golner A, Bone F, Baldo M, Riches M, Mellors JW, Tobin NH, Browning R, Persaud D, Bryson Y, International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) P1107 Team. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell. 2023 03 16; 186(6):1115-1126.e8. PMID: 36931242; PMCID: PMC10616809.
      Citations: 34     Fields:    Translation:HumansCells
    14. Alhomoud M, Chokr N, Gomez-Arteaga A, Chen Z, Escalon JG, Legasto AC, Brusca-Augello G, Yamshon S, Plate M, Zappetti D, Hsu JM, Phillips A, Mayer S, Shore T, Van Besien K. Screening Chest CT Prior to Allogenic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023 05; 29(5):326.e1-326.e10. PMID: 36739088.
      Citations: 2     Fields:    Translation:Humans
    15. Satlin MJ, Chen L, Douglass C, Hovan M, Davidson E, Soave R, La Spina M, Gomez-Arteaga A, van Besien K, Mayer S, Phillips A, Hsu JM, Malherbe R, Small CB, Jenkins SG, Westblade LF, Kreiswirth BN, Walsh TJ. Reply to Caldwell et al. Clin Infect Dis. 2022 08 24; 75(1):180-181. PMID: 34864913; PMCID: PMC9402634.
      Citations:    Fields:    
    16. Gokozan HN, Ouseph MM, Carniello JVS, Besien KV, Patel SS. Now you see me, now you don't: Isolated central nervous system recurrence of CD19-negative diffuse large B-cell lymphoma following CD19-directed CAR T-cell treatment. Cytopathology. 2022 11; 33(6):757-759. PMID: 35713946.
      Citations:    Fields:    Translation:HumansCells
    17. Chaekal OK, Gomez-Arteaga A, Chen Z, Soave R, Shore T, Mayer S, Phillips A, Hsu JM, Drelick A, Kodiyanplakkal RPL, Plate M, Satlin MJ, van Besien K. Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell-Depleted Stem Cell Transplantation. Transplant Cell Ther. 2022 09; 28(9):618.e1-618.e10. PMID: 35724850; PMCID: PMC9213029.
      Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
    18. Elhadad S, Chadburn A, Magro C, Van Besien K, Roberson EDO, Atkinson JP, Terry H, Greenberg J, Reid W, Chapin J, Copertino D, Geramfard S, Rodriguez LB, Orfali N, Gerghis U, Shore T, Mayer S, Ahamed J, Laurence J. C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant. 2022 09; 57(9):1445-1447. PMID: 35661836.
      Citations: 4     Fields:    Translation:Humans
    19. Gomez-Arteaga A, van Besien K. Allogeneic transplant graft source - conditioning - GVHD prophylaxis: don't mix and match! Leuk Lymphoma. 2022 01; 63(1):7-9. PMID: 34818964.
      Citations: 1     Fields:    Translation:Humans
    20. Alhomoud M, Williams A, Magro C, Van Besien K, Vesole DH, Laurence J. Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults. Leuk Lymphoma. 2022 02; 63(2):473-477. PMID: 34668824.
      Citations: 1     Fields:    Translation:Humans
    21. Chaekal OK, Soave R, Chen Z, Shore T, Mayer S, Phillips A, Mei Hsu J, Gomez-Arteaga A, Rennert H, Drelick A, Orfali N, Walsh TJ, Small CB, Kodiyanplakkal RPL, Plate M, Satlin MJ, van Besien K. Adenovirus viremia after in vivo T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes. Leuk Lymphoma. 2022 02; 63(2):435-442. PMID: 34643477.
      Citations: 1     Fields:    Translation:HumansCells
    22. Satlin MJ, Chen L, Douglass C, Hovan M, Davidson E, Soave R, La Spina M, Gomez-Arteaga A, van Besien K, Mayer S, Phillips A, Hsu JM, Malherbe R, Small CB, Jenkins SG, Westblade LF, Kreiswirth BN, Walsh TJ. Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2021 10 05; 73(7):1257-1265. PMID: 33956965; PMCID: PMC8492119.
      Citations: 15     Fields:    Translation:Humans
    23. Orfali N, Zhang MJ, Allbee-Johnson M, Boelens JJ, Artz AS, Brunstein CG, McNiece IK, Milano F, Abid MB, Chee L, Grunwald MR, Hematti P, Hsu J, Lazarus HM, Munshi PN, Prestidge T, Ringden O, Rizzieri D, Riches ML, Seo S, Solh M, Solomon S, Szwajcer D, Yared J, van Besien K, Eapen M, Diaz MA. Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplant Cell Ther. 2021 12; 27(12):993.e1-993.e8. PMID: 34507002; PMCID: PMC8671234.
      Citations: 3     Fields:    Translation:HumansCells
    24. van Besien K, Gomez-Arteaga A. Maintenance therapy after allogeneic transplant for acute myeloid leukemia: great expectations. Leuk Lymphoma. 2021 10; 62(10):2306-2309. PMID: 34586001.
      Citations:    Fields:    Translation:Humans
    25. Sugita M, Wilkes DC, Bareja R, Eng KW, Nataraj S, Jimenez-Flores RA, Yan L, De Leon JP, Croyle JA, Kaner J, Merugu S, Sharma S, MacDonald TY, Noorzad Z, Panchal P, Pancirer D, Cheng S, Xiang JZ, Olson L, Van Besien K, Rickman DS, Mathew S, Tam W, Rubin MA, Beltran H, Sboner A, Hassane DC, Chiosis G, Elemento O, Roboz GJ, Mosquera JM, Guzman ML. Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ Precis Oncol. 2021 May 26; 5(1):44. PMID: 34040147; PMCID: PMC8155064.
      Citations: 20     
    26. Orfali N, Jhanwar Y, Koo C, Pasciolla M, Baldo M, Cuvilly E, Furman R, Gergis U, Greenberg J, Guarneri D, Hsu JM, Leonard JP, Mark T, Mayer S, Maignan K, Martin P, Opong A, Pearse R, Phillips A, Rossi A, Ruan J, Rutherford SC, Ryan J, Suhu G, Van Besien K, Shore T. Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leuk Lymphoma. 2021 07; 62(7):1629-1638. PMID: 33586581.
      Citations:    Fields:    Translation:Humans
    27. Plate M, van Besien K. Is less more? Viewpoint on empiric vancomycin therapy of fever and neutropenia after allogeneic stem cell transplantation. Leuk Lymphoma. 2021 02; 62(2):255-256. PMID: 33356693.
      Citations:    Fields:    Translation:Humans
    28. Neelapu SS, Adkins S, Ansell SM, Brody J, Cairo MS, Friedberg JW, Kline JP, Levy R, Porter DL, van Besien K, Werner M, Bishop MR. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer. 2020 12; 8(2). PMID: 33361336; PMCID: PMC7768967.
      Citations: 11     Fields:    Translation:Humans
    29. van Besien K, Orfali N, Shore T. Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma. JAMA Oncol. 2020 12 01; 6(12):1983-1984. PMID: 33151264.
      Citations:    Fields:    Translation:Humans
    30. Chaekal OK, Scaradavou A, Masson Frenet E, Albano MS, Cushing M, Desai P, Dobrila L, Gergis U, Guarneri D, Hsu JM, Lee S, Mayer SA, Phillips AA, Orfali N, Ritchie EK, Roboz GJ, Romeo C, Samuel MS, Shore T, van Besien K. Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Adv. 2020 10 27; 4(20):5146-5156. PMID: 33091124; PMCID: PMC7594383.
      Citations: 3     Fields:    Translation:Humans
    31. Rogers WS, Westblade LF, Soave R, Jenkins SG, van Besien K, Singh HK, Walsh TJ, Small CB, Shore T, Crawford CV, Satlin MJ. Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2020 10 23; 71(7):1693-1700. PMID: 31687767.
      Citations: 8     Fields:    Translation:HumansCells
    32. Chaekal OK, van Besien K. Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected? Leuk Lymphoma. 2020 12; 61(12):2783-2784. PMID: 32924711.
      Citations:    Fields:    Translation:Humans
    33. Elhadad S, Chapin J, Copertino D, Van Besien K, Ahamed J, Laurence J. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clin Exp Immunol. 2021 01; 203(1):96-104. PMID: 32681658; PMCID: PMC7405159.
      Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
    34. Shah MA, Emlen MF, Shore T, Mayer S, Leonard JP, Rossi A, Martin P, Ritchie E, Niesvizky R, Pastore R, Cigler T, De Sancho M, Scheff R, Van Besien K, Roboz G, Nanus D, Goldstein P, Scrimenti L, Hidalgo M. Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. CA Cancer J Clin. 2020 09; 70(5):349-354. PMID: 32662880; PMCID: PMC7404745.
      Citations: 12     Fields:    Translation:HumansCellsPHPublic Health
    35. Brown M, Abasov R, Salerno D, Shore TB, Gergis U, Mayer S, Phillips A, Hsu J, Kodiyanplakkal RPL, Pasciolla M, van Besien K. Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2020 12; 61(12):3024-3026. PMID: 32654572.
      Citations: 1     Fields:    Translation:Humans
    36. Mina A, van Besien K, Platanias LC. Hematological manifestations of COVID-19. Leuk Lymphoma. 2020 12; 61(12):2790-2798. PMID: 32643489.
      Citations: 17     Fields:    Translation:HumansCellsPHPublic Health
    37. Salvatore M, Laplante JM, Soave R, Orfali N, Plate M, van Besien K, St George K. Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir. Transpl Infect Dis. 2020 Aug; 22(4):e13336. PMID: 32449254.
      Citations: 3     Fields:    Translation:Humans
    38. Gomez-Arteaga A, Orfali N, Guarneri D, Cushing MM, Gergis U, Hsu J, Hsu YS, Mayer SA, Phillips AA, Chase SA, Mokhtar AE, Shore TB, Van Besien K. Cord blood transplants supported by unrelated donor CD34+ progenitor cells. Bone Marrow Transplant. 2020 12; 55(12):2298-2307. PMID: 32518291.
      Citations: 1     Fields:    Translation:Humans
    39. Hsu J, Van Besien K, Baron F. Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation? Leuk Lymphoma. 2020 07; 61(7):1529-1534. PMID: 32476524.
      Citations:    Fields:    Translation:Humans
    40. Ruan J, Yamshon S, van Besien K, Martin P. An update on options of therapy for aggressive mantle cell lymphoma. Leuk Lymphoma. 2020 09; 61(9):2036-2049. PMID: 32336184.
      Citations:    Fields:    Translation:Humans
    41. van Besien KW, Orfali N. Alternative Donor Transplantation for Lymphoid Malignancies: How Far We Have Come. J Clin Oncol. 2020 05 10; 38(14):1501-1504. PMID: 32142395.
      Citations: 1     Fields:    Translation:Humans
    42. Weisdorf D, Cooley S, Wang T, Trachtenberg E, Vierra-Green C, Spellman S, Sees JA, Spahn A, Vogel J, Fehniger TA, Woolfrey AE, Devine SM, Ross M, Waller EK, Sobecks RM, McGuirk J, Oran B, Farag SS, Shore T, Van Besien K, Marsh SGE, Guethlein LA, Parham P, Miller JS. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Adv. 2020 02 25; 4(4):740-754. PMID: 32092137; PMCID: PMC7042994.
      Citations: 29     Fields:    Translation:Humans
    43. Orfali N, van Besien K. Combining haplo-identical and cord blood stem cell grafts - might the whole be greater than the sum of its parts? Leuk Lymphoma. 2020 04; 61(4):753-756. PMID: 32048529.
      Citations: 1     Fields:    Translation:Humans
    44. Awasthi R, Pacaud L, Waldron E, Tam CS, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner-Johnston ND, Schuster SJ, Salles G, Maziarz RT, Del Corral C, Chu J, Gershgorin I, Pruteanu-Malinici I, Chakraborty A, Mueller KT, Waller EK, Jäger U, Kersten MJ, Anak Ö. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 2020 02 11; 4(3):560-572. PMID: 32045475; PMCID: PMC7013261.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    45. Sfeir MM, Gamaletsou MN, Schuetz AN, Soave R, Van Besien K, Small CB, Perlin DS, Walsh TJ, Jiménez-Ortigosa C. Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant Candida tropicalis: An Emerging Threat to Immunocompromised Patients with Hematological Malignancies. J Fungi (Basel). 2020 01 31; 6(1). PMID: 32024039; PMCID: PMC7151208.
      Citations: 7     
    46. Hsu J, Chen Z, Shore T, Gergis U, Mayer S, Phillips A, Guarner D, Hsu YM, Cushing MM, Van Besien K. Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies. Biol Blood Marrow Transplant. 2020 04; 26(4):789-797. PMID: 31891814.
      Citations: 5     Fields:    Translation:Humans
    47. Kodiyanplakkal RPL, Laplante JM, Westblade LF, van Besien K, Salvatore M, St George K. Detection and Characterization of Influenza B Virus With Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient. Open Forum Infect Dis. 2019 Dec; 6(12):ofz493. PMID: 32128335; PMCID: PMC7047943.
      Citations: 1     
    48. Vedvyas Y, McCloskey JE, Yang Y, Min IM, Fahey TJ, Zarnegar R, Hsu YS, Hsu JM, Van Besien K, Gaudet I, Law P, Kim NJ, Hofe EV, Jin MM. Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Sci Rep. 2019 07 23; 9(1):10634. PMID: 31337787; PMCID: PMC6650612.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    49. Choe HK, van Besien K. Donor graft genotypes versus leukemia. Leuk Lymphoma. 2019 07; 60(7):1606-1607. PMID: 31238818.
      Citations:    Fields:    Translation:Humans
    50. van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867. PMID: 31217161; PMCID: PMC6595267.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    51. Gergis U, van Besien K. Tocilizumab, in search for a role in acute GVHD. Leuk Lymphoma. 2019 09; 60(9):2101-2103. PMID: 31238760.
      Citations: 1     Fields:    Translation:HumansAnimals
    52. Gomez-Arteaga A, Mark TM, Guarneri D, Christos PJ, Gergis U, Greenberg JD, Hsu J, Mayer SA, Niesvizky R, Pearse RN, Phillips AA, Rossi A, Coleman M, van Besien K, Shore TB. High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2019 12; 54(12):2027-2038. PMID: 31190006.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    53. Allan JN, Van Besien K. It's not all about the CNS. High dose methotrexate in DLBCL. Leuk Lymphoma. 2019 08; 60(8):1845-1847. PMID: 31120336.
      Citations: 1     Fields:    Translation:Humans
    54. Gomez-Arteaga A, Margolskee E, Wei MT, van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019 07; 60(7):1626-1631. PMID: 30997845; PMCID: PMC8162842.
      Citations: 16     Fields:    Translation:Humans
    55. Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, Hsu J, Phillips AA, Mayer SA, Singh AD, Soave R, Rossi A, Small CB, Walsh TJ, Rennert H, Shore TB. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leuk Lymphoma. 2019 07; 60(7):1693-1696. PMID: 30741059.
      Citations: 15     Fields:    Translation:HumansCells
    56. Glynn S, Lipkin S, Zhang T, Sboner A, Elemento O, Van Besien K, Beltran H. The application of precision medicine in diagnosing familial Mediterranean fever. Leuk Lymphoma. 2019 08; 60(8):2091-2093. PMID: 30698071.
      Citations:    Fields:    Translation:HumansCells
    57. Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu H. Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. Exp Hematol Oncol. 2019; 8:1. PMID: 30622841; PMCID: PMC6317199.
      Citations: 5     
    58. Satlin MJ, Chavda KD, Baker TM, Chen L, Shashkina E, Soave R, Small CB, Jacobs SE, Shore TB, van Besien K, Westblade LF, Schuetz AN, Fowler VG, Jenkins SG, Walsh TJ, Kreiswirth BN. Colonization With Levofloxacin-resistant Extended-spectrum ß-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis. 2018 11 13; 67(11):1720-1728. PMID: 29701766; PMCID: PMC6233682.
      Citations: 29     Fields:    Translation:HumansCells
    59. Gergis U, Frenet EM, Shore T, Mayer S, Phillips A, Hsu JM, Roboz G, Ritchie E, Scandura J, Lee S, Desai P, Samuel M, Ball J, Blanco A, Romeo C, Albano MS, Dobrila L, Scaradavou A, van Besien K. Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. Biol Blood Marrow Transplant. 2019 03; 25(3):466-473. PMID: 30414955.
      Citations: 2     Fields:    Translation:Humans
    60. Eichenberger EM, Soave R, Zappetti D, Small CB, Shore T, van Besien K, Douglass C, Westblade LF, Satlin MJ. Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2019 07; 54(7):1058-1066. PMID: 30385869; PMCID: PMC7091595.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    61. Choe H, Gergis U, Hsu J, Phillips A, Shore T, Christos P, van Besien K, Mayer S. Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies. Biol Blood Marrow Transplant. 2019 02; 25(2):e60-e64. PMID: 30661542.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    62. Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018 09; 103(9):1577. PMID: 30171018; PMCID: PMC6119146.
      Citations: 3     Fields:    
    63. Chaekal OK, van Besien K. A renaissance for autologous transplantation in follicular lymphoma? Leuk Lymphoma. 2019 01; 60(1):3-5. PMID: 29966478.
      Citations: 1     Fields:    Translation:Humans
    64. Reich-Slotky R, Makhani SS, Vasovic LV, Pearse RN, Rossi A, Philips A, Cushing MM, Singh AD, van Besien K. Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. Leuk Lymphoma. 2018 12; 59(12):2829-2835. PMID: 29790808.
      Citations:    Fields:    Translation:HumansCells
    65. Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018 05; 103(5):770-777. PMID: 29419425; PMCID: PMC5927989.
      Citations: 25     Fields:    Translation:HumansCells
    66. Sfeir MM, Schuetz A, Van Besien K, Borczuk AC, Soave R, Jenkins SG, Walsh TJ, Small CB. Mycobacterial spindle cell pseudotumour: epidemiology and clinical outcomes. J Clin Pathol. 2018 Jul; 71(7):626-630. PMID: 29367301.
      Citations: 10     Fields:    Translation:HumansCells
    67. Kebriaei P, Cutler C, de Lima M, Giralt S, Lee SJ, Marks D, Merchant A, Stock W, van Besien K, Stelljes M. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018 04; 53(4):449-456. PMID: 29330398; PMCID: PMC5897380.
      Citations: 51     Fields:    Translation:Humans
    68. Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004. PMID: 29288821.
      Citations: 7     Fields:    Translation:Humans
    69. Reich-Slotky R, Cushing MM, Hsu YS, Ancharski M, Rojas JM, Scrimenti LM, Robilio S, Assalone D, Roselli T, Guarneri D, Vasovic LV, Goel R, Shore T, van Besien K. Validating and implementing the use of an infusion pump for the administration of thawed hematopoietic progenitor cells-a single-institution experience. Transfusion. 2018 02; 58(2):339-344. PMID: 29193156.
      Citations: 1     Fields:    Translation:HumansCells
    70. Hsu J, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, Smith SM, Greenberg J, Kline J, Ferrante R, Phillips AA, Gergis U, Liu H, Stock W, Cushing M, Shore TB, van Besien K. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 02; 24(2):359-365. PMID: 29128555; PMCID: PMC6574086.
      Citations: 5     Fields:    Translation:Humans
    71. Singh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U, Mayer S, Phillips A, Hsu JM, Niesvizky R, Mark TM, Pearse R, Rossi A, van Besien K. Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. Biol Blood Marrow Transplant. 2018 02; 24(2):288-293. PMID: 29061534; PMCID: PMC6574227.
      Citations: 6     Fields:    Translation:HumansCells
    72. Liu C, Frank DN, Horch M, Chau S, Ir D, Horch EA, Tretina K, van Besien K, Lozupone CA, Nguyen VH. Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and donors. Bone Marrow Transplant. 2017 Dec; 52(12):1643-1650. PMID: 28967895.
      Citations: 34     Fields:    Translation:Humans
    73. Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep; 4(9):e431-e442. PMID: 28826616; PMCID: PMC5718627.
      Citations: 63     Fields:    Translation:HumansCTClinical Trials
    74. Choe HK, van Besien K. Earlier may be better: the role of extracorporeal photopheresis (ECP) as prevention of GVHD after allogeneic transplant. Leuk Lymphoma. 2018 02; 59(2):272-273. PMID: 28812411.
      Citations: 3     Fields:    Translation:Humans
    75. Choe HK, van Besien K. Against the odds: haplo-cord grafts protect from GvHD and relapse. Bone Marrow Transplant. 2017 12; 52(12):1590-1591. PMID: 28628090.
      Citations: 3     Fields:    Translation:Humans
    76. Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data. Leuk Lymphoma. 2018 01; 59(1):256-258. PMID: 28573908.
      Citations: 3     Fields:    Translation:HumansCells
    77. Kanaan SB, Gammill HS, Harrington WE, De Rosa SC, Stevenson PA, Forsyth AM, Allen J, Cousin E, van Besien K, Delaney CS, Nelson JL. Maternal microchimerism is prevalent in cord blood in memory T cells and other cell subsets, and persists post-transplant. Oncoimmunology. 2017; 6(5):e1311436. PMID: 28638735; PMCID: PMC5467984.
      Citations: 26     Fields:    
    78. Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Jun; 23(6):930-937. PMID: 28285081.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    79. Choe HK, Gergis U, Mayer SA, Nagar H, Phillips AA, Shore TB, Smith MJ, van Besien K. The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. Transplantation. 2017 Jan; 101(1):e34-e38. PMID: 27764032.
      Citations: 4     Fields:    Translation:Humans
    80. Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90. PMID: 28018601; PMCID: PMC5168808.
      Citations: 14     Fields:    
    81. Mayer S, van Besien K. Second allogeneic transplantation: ever? never? or sometimes. Leuk Lymphoma. 2017 06; 58(6):1279-1280. PMID: 27842447.
      Citations:    Fields:    Translation:Humans
    82. van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T. Haplo-cord transplant: HLA-matching determines graft dominance. Leuk Lymphoma. 2017 06; 58(6):1512-1514. PMID: 27786572; PMCID: PMC5832029.
      Citations: 3     Fields:    Translation:HumansCells
    83. Rojek K, Nickels E, Neistadt B, Marquez R, Wickrema A, Artz A, van Besien K, Larson RA, Lee MK, Segal JP, King MC, Walsh T, Shimamura A, Keel SB, Churpek JE, Godley LA. Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2016 11; 22(11):2100-2103. PMID: 27497531; PMCID: PMC5592729.
      Citations: 22     Fields:    Translation:Humans
    84. van Besien K, Childs R. Haploidentical cord transplantation-The best of both worlds. Semin Hematol. 2016 10; 53(4):257-266. PMID: 27788764.
      Citations: 12     Fields:    Translation:Humans
    85. Dierickx D, Sprangers B, Van Besien K. HLA: revisiting an old suspect in the complex pathogenesis of posttransplant lymphoproliferative disorders. Leuk Lymphoma. 2016 10; 57(10):2241-2. PMID: 27379564.
      Citations:    Fields:    Translation:Humans
    86. van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T. Cord blood chimerism and relapse after haplo-cord transplantation. Leuk Lymphoma. 2017 02; 58(2):288-297. PMID: 27333804; PMCID: PMC5830127.
      Citations: 12     Fields:    Translation:Humans
    87. Thomas CM, Ippoliti C, Roboz GJ, Feldman E, Savva D, James S, van Besien K. Clofarabine as a bridge to hematopoietic stem cell transplant. Leuk Lymphoma. 2017 01; 58(1):230-232. PMID: 27240704.
      Citations: 1     Fields:    Translation:Humans
    88. Marino SR, Lee SM, Binkowski TA, Wang T, Haagenson M, Wang HL, Maiers M, Spellman S, van Besien K, Lee SJ, Karrison T, Artz A. Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task. Bone Marrow Transplant. 2016 Oct; 51(10):1342-1349. PMID: 27214075; PMCID: PMC5052106.
      Citations: 5     Fields:    Translation:Humans
    89. Isa F, Saito K, Huang YT, Schuetz A, Babady NE, Salvatore S, Pessin M, van Besien K, Perales MA, Giralt S, Sepkowitz K, Papanicolaou GA, Soave R, Kamboj M. Implementation of Molecular Surveillance After a Cluster of Fatal Toxoplasmosis at 2 Neighboring Transplant Centers. Clin Infect Dis. 2016 08 15; 63(4):565-8. PMID: 27199460; PMCID: PMC4967604.
      Citations: 7     Fields:    Translation:HumansAnimalsPHPublic Health
    90. Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P, Arock M, Horny HP. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant. 2016 08; 22(8):1348-1356. PMID: 27131865.
      Citations: 32     Fields:    Translation:Humans
    91. Cirrone F, Ippoliti C, Wang H, Zhou XK, Gergis U, Mayer S, Shore T, van Besien K. Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation. Leuk Lymphoma. 2016 11; 57(11):2555-9. PMID: 26984480.
      Citations: 9     Fields:    Translation:HumansCells
    92. Salvatore M, Satlin MJ, Jacobs SE, Jenkins SG, Schuetz AN, Moss RB, Van Besien K, Shore T, Soave R. DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. Biol Blood Marrow Transplant. 2016 May; 22(5):965-70. PMID: 26904972.
      Citations: 27     Fields:    Translation:HumansCellsCTClinical Trials
    93. Tsai SB, Liu H, Shore T, Fan Y, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Martinez G, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072. PMID: 26912055; PMCID: PMC4867292.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    94. Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E, Scandura J, Wang H, Zhou XK, Silver RT, van Besien K. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clin Lymphoma Myeloma Leuk. 2016 May; 16(5):297-303. PMID: 27025789.
      Citations: 10     Fields:    Translation:Humans
    95. van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43. PMID: 26869630; PMCID: PMC5004373.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    96. Reich-Slotky R, Bachegowda LS, Ancharski M, Gergis U, van Besien K, Cushing MM. Engraftment for CD34 selected stem cell products is not compromised by cryopreservation. Transfusion. 2016 Apr; 56(4):893-8. PMID: 26661996.
      Citations: 4     Fields:    Translation:HumansCells
    97. Patel K, Parmar S, Shah S, Shore T, Gergis U, Mayer S, van Besien K. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Mar; 22(3):456-61. PMID: 26524732; PMCID: PMC7128235.
      Citations: 5     Fields:    Translation:Humans
    98. van Besien K. Allografting versus Autografting for Follicular Lymphoma: An Ongoing Conundrum. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2035-2036. PMID: 26463649.
      Citations:    Fields:    Translation:Humans
    99. Jacobs SE, Lamson DM, Soave R, Guzman BH, Shore TB, Ritchie EK, Zappetti D, Satlin MJ, Leonard JP, van Besien K, Schuetz AN, Jenkins SG, George KS, Walsh TJ. Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy. J Clin Virol. 2015 Oct; 71:51-8. PMID: 26370315; PMCID: PMC4750469.
      Citations: 18     Fields:    Translation:HumansCells
    100. Yew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, Imoto S, Miyano S, Bishop MR, Stock W, Nakamura Y. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015 Sep; 50(9):1227-34. PMID: 26052909; PMCID: PMC4559843.
      Citations: 65     Fields:    Translation:HumansCellsCTClinical Trials
    101. Storch E, Mark T, Avecilla S, Pagan C, Rhodes J, Shore T, van Besien K, Cushing M. A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration. Transfusion. 2015 Aug; 55(8):2010-6. PMID: 25808119.
      Citations: 3     Fields:    Translation:HumansCells
    102. Lindemans CA, van Besien K. Topping it up: methods to improve cord blood transplantation outcomes by increasing the number of CD34+ cells. Cytotherapy. 2015 Jun; 17(6):723-729. PMID: 25791069.
      Citations: 6     Fields:    Translation:Humans
    103. Phillips AA, van Besien K. A new "age" for high dose therapy and autologous stem cell transplant. Leuk Lymphoma. 2015; 56(8):2233-4. PMID: 25641430.
      Citations:    Fields:    Translation:Humans
    104. Liu H, van Besien K. Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors? Curr Hematol Malig Rep. 2015 Mar; 10(1):1-7. PMID: 25667129.
      Citations: 6     Fields:    Translation:Humans
    105. Segovia J, van Besien K. Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly maligned. Leuk Lymphoma. 2015 Apr; 56(4):841-2. PMID: 25495172.
      Citations: 2     Fields:    Translation:Humans
    106. Reich-Slotky R, Bachegowda LS, Ancharski M, Mendeleyeva L, Rubinstein P, Rennert H, Shore T, van Besien K, Cushing M. How we handled the dextran shortage: an alternative washing or dilution solution for cord blood infusions. Transfusion. 2015 Jun; 55(6):1147-53. PMID: 25652820.
      Citations: 2     Fields:    Translation:HumansCells
    107. Copelan EA, Avalos BR, Ahn KW, Zhu X, Gale RP, Grunwald MR, Hamadani M, Hamilton BK, Hale GA, Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ, Inamoto Y, Kamble RT, Schouten HC, Wirk B, Litzow MR, Aljurf MD, van Besien KW, Ustun C, Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, Horowitz MM, Arora M, Szer J, Loren AW, Alyea EP, Cortes J, Maziarz RT, Kalaycio ME, Saber W. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. Biol Blood Marrow Transplant. 2015 Mar; 21(3):552-8. PMID: 25528388; PMCID: PMC4329042.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    108. Preeshagul IR, Van Besien K, Mark TM. Controversies in multiple myeloma: to transplant or not? Curr Hematol Malig Rep. 2014 Dec; 9(4):360-7. PMID: 25145553.
      Citations: 1     Fields:    Translation:Humans
    109. Chapin J, Shore T, Forsberg P, Desman G, Van Besien K, Laurence J. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol. 2014 Sep; 12(9):565-73. PMID: 25654478.
      Citations: 21     Fields:    Translation:Humans
    110. van Besien K. Advances in umbilical cord blood transplant: an overview of the 12th International Cord Blood Symposium, San Francisco, 5-7 June 2014. Leuk Lymphoma. 2015 Apr; 56(4):877-81. PMID: 25058374.
      Citations:    Fields:    Translation:Humans
    111. van Besien K, Furman RR. To the end of chronic lymphocytic leukemia: what should be the role of allogeneic transplant? Leuk Lymphoma. 2014 Jun; 55(6):1221-2. PMID: 24745938.
      Citations:    Fields:    Translation:HumansCells
    112. Polliack A, Seymour J, Van Besien K, Treadway A. Statement of Retraction: Huang H, Wu D, Fu J, Chen G. "multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid". Leuk Lymphoma. 2014 Jun; 55(6):1437. PMID: 24850142.
      Citations:    Fields:    
    113. Petri CR, O'Donnell PH, Cao H, Artz AS, Stock W, Wickrema A, Hard M, van Besien K. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014 Dec; 55(12):2866-73. PMID: 24564572; PMCID: PMC4477686.
      Citations: 9     Fields:    Translation:Humans
    114. Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9. PMID: 24816237; PMCID: PMC4116837.
      Citations: 103     Fields:    Translation:Humans
    115. van Besien K. Advances in umbilical cord blood transplant: a summary of the 11th International Cord Blood Symposium, San Francisco, 6-8 June 2013. Leuk Lymphoma. 2014 Aug; 55(8):1735-8. PMID: 24180330.
      Citations: 3     Fields:    Translation:Humans
    116. Satlin MJ, Soave R, Racanelli AC, Shore TB, van Besien K, Jenkins SG, Walsh TJ. The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. Leuk Lymphoma. 2014 Dec; 55(12):2858-65. PMID: 24559288; PMCID: PMC4316723.
      Citations: 15     Fields:    Translation:HumansCells
    117. McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Vij R, Warlick ED, Weisdorf DJ, Freytes CO, Olsson R, Akpek G, Socie G. Allotransplantation for patients age =40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant. 2014 Jul; 20(7):960-8. PMID: 24641829; PMCID: PMC4057955.
      Citations: 13     Fields:    Translation:Humans
    118. Kosuri S, van Besien K. Great expectations? Conditioning with busulfan, melphalan and thiotepa in recurrent Hodgkin lymphoma. Leuk Lymphoma. 2014 Mar; 55(3):476-7. PMID: 24471910.
      Citations:    Fields:    Translation:Humans
    119. Gergis U, Mayer S, Gordon B, Mark T, Pearse R, Shore T, Van Besien K. A strategy to reduce donor-specific HLA Abs before allogeneic transplantation. Bone Marrow Transplant. 2014 May; 49(5):722-4. PMID: 24535131.
      Citations: 9     Fields:    Translation:Humans
    120. Eikmans M, van Halteren AG, van Besien K, van Rood JJ, Drabbels JJ, Claas FH. Naturally acquired microchimerism: implications for transplantation outcome and novel methodologies for detection. Chimerism. 2014; 5(2):24-39. PMID: 24762743; PMCID: PMC4199805.
      Citations: 18     Fields:    Translation:HumansAnimals
    121. Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014 Jan; 20(1):89-97. PMID: 24161923; PMCID: PMC3886623.
      Citations: 66     Fields:    Translation:Humans
    122. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 05; 122(24):3863-70. PMID: 24065243; PMCID: PMC3854108.
      Citations: 64     Fields:    Translation:Humans
    123. Evens AM, Rosen ST, Helenowski I, Kline J, Larsen A, Colvin J, Winter JN, van Besien KM, Gordon LI, Smith SM. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. Br J Haematol. 2013 Oct; 163(1):55-61. PMID: 23927371.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    124. Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013 Sep 01; 31(25):3100-9. PMID: 23897963; PMCID: PMC3753702.
      Citations: 86     Fields:    Translation:Humans
    125. Polliack A, Van Besien K, Seymour J, Treadway A. Statement of retraction. Avilés A, Fernándezb R, Pérez F, Nambo MJ, Neri N, Talavera A, Castañeda C,González M, Cleto. Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma. 2013 Jul; 54(7):1571. PMID: 23777388.
      Citations:    Fields:    
    126. Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Artz A, Stock W. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov; 48(11):1437-43. PMID: 23771005; PMCID: PMC4279870.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    127. Gergis U, Roboz G, Shore T, Ritchie E, Mayer S, Wissa U, McKenna M, Christos P, Pearse R, Mark T, Scandura J, van Besien K, Feldman E. A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1040-5. PMID: 23648237.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    128. Lin RJ, Larson RA, van Besien K, Rich ES. Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation. Case Rep Hematol. 2013; 2013:140138. PMID: 23607004; PMCID: PMC3625539.
      Citations:    
    129. van Besien K, Liu HT, Artz A. Microchimerism and allogeneic transplantation: we need the proof in the pudding. Chimerism. 2013 Jul-Sep; 4(3):109-10. PMID: 23511912; PMCID: PMC3782544.
      Citations: 1     Fields:    Translation:Humans
    130. Jain N, Liu H, Artz AS, Anastasi J, Odenike O, Godley LA, Joseph L, Marino S, Kline J, Nguyen V, Schouten V, Kunnavakkam R, Larson RA, Stock W, Ulaszek J, Savage PA, Wickrema A, van Besien K. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma. 2013 Jun; 54(6):1242-9. PMID: 23088744.
      Citations: 11     Fields:    Translation:HumansCells
    131. Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):831-7. PMID: 23454184; PMCID: PMC3985064.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    132. van Besien K, Shore T, Cushing M. Peripheral-blood versus bone marrow stem cells. N Engl J Med. 2013 01 17; 368(3):287-8. PMID: 23323912.
      Citations: 3     Fields:    Translation:Humans
    133. Churpek JE, Pro B, van Besien K, Kline J, Conner K, Wade JL, Hagemeister F, Karrison T, Smith SM. A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. Cancer. 2013 May 01; 119(9):1683-9. PMID: 23310949; PMCID: PMC4332882.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    134. Artz AS, van Besien K. Pre-transplant serum ferritin is prognostic but is it useful? Leuk Lymphoma. 2013 Jun; 54(6):1133-4. PMID: 23216268.
      Citations:    Fields:    Translation:Humans
    135. van Besien K. Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. Hematology Am Soc Hematol Educ Program. 2013; 2013:56-62. PMID: 24319163.
      Citations: 20     Fields:    Translation:Humans
    136. Churpek JE, Nickels E, Marquez R, Rojek K, Liu B, Lorenz R, Lepore J, Madzo J, Wickrema A, Artz AS, van Besien K, Godley LA. Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood. 2012 Dec 20; 120(26):5247-9. PMID: 23258901.
      Citations: 8     Fields:    Translation:Humans
    137. Muffly LS, Boulukos M, Swanson K, Kocherginsky M, Cerro PD, Schroeder L, Pape L, Extermann M, Van Besien K, Artz AS. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant. 2013 Mar; 19(3):429-34. PMID: 23160006.
      Citations: 57     Fields:    Translation:Humans
    138. Geslain R, Uddin S, Liu H, Jiang H, van Besien K, Pan T, Wickrema A. Distinct functions of erythropoietin and stem cell factor are linked to activation of mTOR kinase signaling pathway in human erythroid progenitors. Cytokine. 2013 Jan; 61(1):329-35. PMID: 23148990.
      Citations: 7     Translation:HumansCells
    139. Van Besien K, Liu H, Jain N, Stock W, Artz A. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013 May; 19(5):682-91. PMID: 23142329; PMCID: PMC3618995.
      Citations: 16     Fields:    Translation:Humans
    140. van Besien K. cGVHD of skin: simple tools, great advances. Blood. 2012 Sep 27; 120(13):2537-8. PMID: 23019199.
      Citations:    Fields:    Translation:Humans
    141. Morawa E, Martin P, Gergis U, van Besien K, Shore T. Autologous stem cell transplant in human immunodeficiency virus-positive patients with lymphoid malignancies: focus on infectious complications. Leuk Lymphoma. 2013 Apr; 54(4):885-8. PMID: 22897727.
      Citations: 3     Fields:    Translation:Humans
    142. Dierickx D, van Besien K. Therapeutic drug monitoring: a way to improve long-term immunological balance? Leuk Lymphoma. 2013 Jan; 54(1):5-6. PMID: 22857003.
      Citations:    Fields:    Translation:HumansCells
    143. Villa CH, Shore T, Van Besien K, Cushing M. Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1867-75. PMID: 22796644.
      Citations: 4     Fields:    Translation:Humans
    144. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81. PMID: 22571201; PMCID: PMC3744390.
      Citations: 419     Fields:    Translation:HumansCTClinical Trials
    145. Richa EM, Kunnavakkam R, Godley LA, Kline J, Odenike O, Larson RA, Nguyen V, Stock W, Wickrema A, Van Besien K, Artz AS. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 2012 Jul; 14(6):707-15. PMID: 22548695.
      Citations: 4     Fields:    Translation:Humans
    146. Cook RJ, Wang Z, Arora M, Lazarus HM, Kasow KA, Champagne MA, Saber W, van Besien KM, Hale GA, Copelan EA, Elmongy M, Ueno NT, Horn BN, Slavin S, Bishop MR, Stadtmauer EA. Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis. Bone Marrow Transplant. 2012 Nov; 47(11):1455-8. PMID: 22465977; PMCID: PMC3951901.
      Citations: 8     Fields:    Translation:Humans
    147. Pai RK, van Besien K, Hart J, Artz AS, O'Donnell PH. Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1552-7. PMID: 22280517; PMCID: PMC4482341.
      Citations: 9     Fields:    Translation:Humans
    148. Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock W. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50. PMID: 21913806.
      Citations: 7     Fields:    Translation:Humans
    149. Zhang MJ, Carreras J, Burns LJ, Gale RP, Isola L, Perales MA, Seftel M, Vose JM, Miller AM, Gibson J, Gross TG, Rowlings PA, Inwards DJ, Pavlovsky S, Martino R, Marks DI, Hale GA, Smith SM, Schouten HC, Slavin S, Klumpp TR, Lazarus HM, van Besien K, Hari PN, Freytes CO. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. Biol Blood Marrow Transplant. 2012 Aug; 18(8):1255-64. PMID: 22198543; PMCID: PMC3376237.
      Citations: 9     Fields:    Translation:Humans
    150. van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, Kline J, Nguyen V, Del Cerro P, Larson RA, Artz AS. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21. PMID: 22079470; PMCID: PMC3423318.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    151. van Besien K. Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. Curr Opin Oncol. 2011 Nov; 23(6):681-91. PMID: 21946246; PMCID: PMC4811671.
      Citations: 8     Fields:    Translation:Humans
    152. Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, Kline J, Nguyen V, Cunningham J, Larson RA, del Cerro P, Schroeder L, Pape L, Stock W, Wickrema A, Artz AS, van Besien K. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011 Dec 08; 118(24):6438-45. PMID: 21976674; PMCID: PMC3236125.
      Citations: 69     Fields:    Translation:HumansCellsCTClinical Trials
    153. Jain N, van Besien K. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin North Am. 2011 Oct; 25(5):1025-48, vi. PMID: 22054733; PMCID: PMC3246008.
      Citations: 5     Fields:    Translation:Humans
    154. Rezania K, Soliven B, Baron J, Lin H, Penumalli V, van Besien K. Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. Leuk Lymphoma. 2012 Mar; 53(3):371-80. PMID: 21864038.
      Citations: 11     Fields:    Translation:Humans
    155. van Besien K, Schouten V, Parsad S, Smith S, Odenike O, Artz AS. Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. Leuk Lymphoma. 2012 Jan; 53(1):158-9. PMID: 21749304.
      Citations: 6     Fields:    Translation:Humans
    156. van Besien K. Stem cell transplantation for indolent lymphoma: a reappraisal. Blood Rev. 2011 Sep; 25(5):223-8. PMID: 21641099; PMCID: PMC3158814.
      Citations: 1     Fields:    Translation:Humans
    157. Ramsdale E, Van Besien K. Allogeneic transplant for peripheral T-cell lymphoma: a sparkle of hope and many questions. Leuk Lymphoma. 2011 Aug; 52(8):1415-7. PMID: 21599586.
      Citations:    Fields:    Translation:Humans
    158. van Besien K, Poiré X. Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Expert Opin Biol Ther. 2011 Aug; 11(8):1099-111. PMID: 21702703; PMCID: PMC3126913.
      Citations: 9     Fields:    Translation:Humans
    159. Greinix HT, van Besien K, Elmaagacli AH, Hillen U, Grigg A, Knobler R, Parenti D, Reddy V, Theunissen K, Michallet M, Flowers ME, UVADEX Chronic GVHD Study Group. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1775-82. PMID: 21621629.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    160. Ramsdale E, van Besien K, Smith SM. Personalized treatment of lymphoma: promise and reality. Semin Oncol. 2011 Apr; 38(2):225-35. PMID: 21421112.
      Citations: 3     Fields:    Translation:Humans
    161. van Besien K. Cord blood transplant: the glass is half full--can we do better? Leuk Lymphoma. 2011 Apr; 52(4):554-5. PMID: 21438826.
      Citations: 2     Fields:    Translation:Humans
    162. Marino SR, Lin S, Maiers M, Haagenson M, Spellman S, Klein JP, Binkowski TA, Lee SJ, van Besien K. Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012 Feb; 47(2):217-26. PMID: 21441965; PMCID: PMC3128239.
      Citations: 17     Fields:    Translation:Humans
    163. van Besien K, Kenkre V, Artz AS. T-cell-depleted reduced-intensity conditioning transplantation for lymphoma: do donor lymphocyte infusions really matter? J Clin Oncol. 2011 Mar 20; 29(9):e243; author reply e244. PMID: 21343548.
      Citations:    Fields:    Translation:HumansCells
    164. Bishop MR, Alyea EP, Cairo MS, Falkenburg JH, June CH, Little RF, Miller JS, Pavletic SZ, Porter DL, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu RS, Giralt S, Kröger N. National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant. 2011 Apr; 17(4):443-54. PMID: 21224011; PMCID: PMC3102296.
      Citations: 18     Fields:    Translation:Humans
    165. Kenkre VP, Horowitz S, Artz AS, Liao C, Cohen KS, Godley LA, Kline JP, Smith SM, Stock W, van Besien K. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011 Feb; 52(2):214-22. PMID: 21142785; PMCID: PMC3617078.
      Citations: 8     Fields:    Translation:Humans
    166. O'Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9. PMID: 20919852; PMCID: PMC4477684.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    167. Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro B. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6. PMID: 20837940; PMCID: PMC3020703.
      Citations: 76     Fields:    Translation:HumansCTClinical Trials
    168. Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JH, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503. PMID: 20699125; PMCID: PMC2955517.
      Citations: 52     Fields:    Translation:Humans
    169. Kline J, Grinblatt D, Zimmerman T, Conner K, Muhs C, Gajewski T, Van Besien K, Smith SM, Poiré X. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50. PMID: 20496994.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    170. Martin PJ, Storer BE, Carpenter PA, Couriel DR, Flowers ME, Gupta V, Hsu JW, Jagasia M, Kitko CL, Maziarz RT, Rowley SD, Shaughnessy PJ, van Besien K, Weisdorf D, Lee SJ. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011 Jan; 17(1):124-32. PMID: 20601033; PMCID: PMC2974028.
      Citations: 17     Fields:    Translation:Humans
    171. Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, Rich ES, Artz A, Van Besien K, Daugherty CK, Zhang Y, Le Beau MM, Stock W, Larson RA. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006. PMID: 20536346.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    172. Godley LA, van Besien K. The next frontier for stem cell transplantation: finding a donor for all. JAMA. 2010 Apr 14; 303(14):1421-2. PMID: 20388899.
      Citations: 3     Fields:    Translation:Humans
    173. Dew A, van Besien K. Stem-cell transplantation for sickle cell disease. N Engl J Med. 2010 Mar 11; 362(10):955; author reply 956. PMID: 20220194.
      Citations:    Fields:    Translation:Humans
    174. Locke FL, Artz A, Rich E, Zhang Y, van Besien K, Stock W. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant. 2010 Dec; 45(12):1692-8. PMID: 20208570.
      Citations: 9     Fields:    Translation:Humans
    175. Bishop MR, Alyea EP, Cairo MS, Falkenburg JH, June CH, Little RF, Miller JS, Pavletic SZ, Porter D, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu R, Giralt S, Kröger N. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 May; 16(5):563-4. PMID: 20202482; PMCID: PMC2996879.
      Citations: 11     Fields:    Translation:HumansPHPublic Health
    176. Oliansky DM, Gordon LI, King J, Laport G, Leonard JP, McLaughlin P, Soiffer RJ, van Besien KW, Werner M, Jones RB, McCarthy PL, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant. 2010 Apr; 16(4):443-68. PMID: 20114084.
      Citations: 17     Fields:    Translation:Humans
    177. Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010 Feb 20; 28(6):1038-46. PMID: 20085936; PMCID: PMC2834429.
      Citations: 88     Fields:    Translation:Humans
    178. Shaughnessy PJ, Bolwell BJ, van Besien K, Mistrik M, Grigg A, Dodds A, Prince HM, Durrant S, Ilhan O, Parenti D, Gallo J, Foss F, Apperley J, Zhang MJ, Horowitz MM, Abhyankar S. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010 Jun; 45(6):1068-76. PMID: 19915634; PMCID: PMC3376382.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    179. Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM, Freytes CO. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1455-64. PMID: 19822306; PMCID: PMC2913553.
      Citations: 21     Fields:    Translation:Humans
    180. van Besien K, Dew A, Lin S, Joseph L, Godley LA, Larson RA, Odenike T, Rich E, Stock W, Wickrema A, Artz AS. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17. PMID: 19821799.
      Citations: 25     Fields:    Translation:Humans
    181. Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD, Bolwell BJ, Gale RP, Goldstein SC, Hale GA, Inwards DJ, Klumpp TR, Marks DI, Maziarz RT, McCarthy PL, Pavlovsky S, Rizzo JD, Shea TC, Schouten HC, Slavin S, Winter JN, van Besien K, Vose JM, Hari PN, Freytes CO. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010 Jan; 16(1):35-45. PMID: 20053330; PMCID: PMC2929576.
      Citations: 30     Fields:    Translation:Humans
    182. Richa E, Papari M, Allen J, Martinez G, Wickrema A, Anastasi J, Van Besien K, Artz A. Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1394-9. PMID: 19822298.
      Citations: 18     Fields:    Translation:Humans
    183. Sharma M, Moore J, Nguyen V, Van Besien K. Fatal CMV pneumonitis in a lymphoma patient treated with rituximab. Am J Hematol. 2009 Sep; 84(9):614-6. PMID: 19676117.
      Citations: 5     Fields:    Translation:Humans
    184. Vose JM, Ho AD, Coiffier B, Corradini P, Khouri I, Sureda A, Van Besien K, Dipersio J. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma. 2009 Sep; 50(9):1412-21. PMID: 19603345.
      Citations: 14     Fields:    Translation:Humans
    185. Loberiza FR, Lee SJ, Freytes CO, Giralt SA, Van Besien K, Kurian S, del Cerro P, Toro JJ, Williams LA, Ketelsen SW, Navarro WH, Rizzo JD. Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009 Aug; 15(8):903-9. PMID: 19589479; PMCID: PMC2911964.
      Citations: 3     Fields:    Translation:Humans
    186. O'Donnell PH, Swanson K, Josephson MA, Artz AS, Parsad SD, Ramaprasad C, Pursell K, Rich E, Stock W, van Besien K. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1038-1048.e1. PMID: 19660716; PMCID: PMC2723723.
      Citations: 28     Fields:    Translation:HumansCells
    187. van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B, Giralt S. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):610-7. PMID: 19361753; PMCID: PMC4348112.
      Citations: 33     Fields:    Translation:Humans
    188. van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R, Nelson G, Fay JW, Champlin RE, Lazarus HM, Vose JM, Hari PN. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):554-63. PMID: 19361747; PMCID: PMC3120935.
      Citations: 16     Fields:    Translation:Humans
    189. Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, DeVetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009 May 21; 113(21):5074-82. PMID: 19270260; PMCID: PMC2686178.
      Citations: 61     Fields:    Translation:Humans
    190. van Besien K, Poiré X. Autologous transplant for primary mediastinal B-cell lymphoma. Expert Rev Hematol. 2009 Feb; 2(1):31-6. PMID: 21082992.
      Citations: 2     Fields:    
    191. Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN, Gale RP, Gibson J, Giralt SA, Goldstein SC, Gupta V, Marks DI, Maziarz RT, Vose JM, Lazarus HM, Anderlini P, Freytes CO. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009 Jan; 15(1):109-17. PMID: 19135949; PMCID: PMC2929570.
      Citations: 37     Fields:    Translation:Humans
    192. Artz A, Larson RA, Kline J, Odenike O, Rich E, Godley L, Stock W, van Besien K, Poiré X. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91. PMID: 19142796; PMCID: PMC3617055.
      Citations: 6     Fields:    Translation:Humans
    193. van Besien K. Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. Hematology Am Soc Hematol Educ Program. 2009; 610-8. PMID: 20008246.
      Citations: 5     Fields:    Translation:Humans
    194. Foss F, van Besien K. Reduced-intensity and nonmyeloablative conditioning regimens. Cancer Treat Res. 2009; 144:209-32. PMID: 19779868.
      Citations:    Fields:    Translation:HumansCells
    195. Lazarus HM, Carreras J, Boudreau C, Loberiza FR, Armitage JO, Bolwell BJ, Gale RP, Gibson J, Hale GA, Inwards DJ, LeMaistre CF, Maharaj D, Marks DI, Miller AM, Pavlovsky S, Schouten HC, van Besien K, Vose JM, Bitran JD, Khouri IF, McCarthy PL, Yu H, Rowlings P, Serna DS, Horowitz MM, Rizzo JD, Center For International Blood & Marrow Transplant Research (CIBMTR), Freytes CO. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008 Dec; 14(12):1323-33. PMID: 19041053; PMCID: PMC2638759.
      Citations: 13     Fields:    Translation:Humans
    196. Calderwood MS, Mauer A, Tolentino J, Flores E, van Besien K, Pursell K, Weber SG. Epidemiology of vancomycin-resistant enterococci among patients on an adult stem cell transplant unit: observations from an active surveillance program. Infect Control Hosp Epidemiol. 2008 Nov; 29(11):1019-25. PMID: 18823273.
      Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
    197. Artz AS, Wickrema A, Dinner S, Godley LA, Kocherginsky M, Odenike O, Rich ES, Stock W, Ulaszek J, Larson RA, van Besien K. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16. PMID: 18940674; PMCID: PMC2668514.
      Citations: 36     Fields:    Translation:Humans
    198. van Besien K, Hari P. Nonmyeloablative conditioning for relapsed follicular lymphoma. Blood. 2008 Sep 15; 112(6):2585-6; author reply 2586-7. PMID: 18779408.
      Citations: 1     Fields:    Translation:Humans
    199. Nguyen V, van Besien K. Late relapse following allogeneic transplant for chronic lymphocytic leukemia: how good are graft versus leukemia effects? Leuk Lymphoma. 2008 Sep; 49(9):1651-2. PMID: 18798096.
      Citations:    Fields:    Translation:Humans
    200. van Besien KW. Superiority of reduced-intensity conditioning for Hodgkin's lymphoma. J Clin Oncol. 2008 Aug 20; 26(24):4045-6; author reply 4046-7. PMID: 18711200.
      Citations:    Fields:    Translation:Humans
    201. Dew A, Collins D, Artz A, Rich E, Stock W, Swanson K, van Besien K. Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options. Biol Blood Marrow Transplant. 2008 Aug; 14(8):938-41. PMID: 18640578; PMCID: PMC2556036.
      Citations: 24     Fields:    Translation:Humans
    202. Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Pavlovsky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus HM, Hari P. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008 Aug; 14(8):904-12. PMID: 18640574; PMCID: PMC3353768.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    203. Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, Bacigalupo A, Kolb HJ, Bouzas L, Michallet M, Prince HM, Knobler R, Parenti D, Gallo J, Greinix HT. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008 Oct 01; 112(7):2667-74. PMID: 18621929.
      Citations: 101     Fields:    Translation:HumansCTClinical Trials
    204. Rosenbaum C, Peace D, Rich E, Van Besien K. Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease. Biol Blood Marrow Transplant. 2008 Jun; 14(6):719-23. PMID: 18489998.
      Citations: 9     Fields:    Translation:Humans
    205. O'Donnell PH, Artz AS, Undevia SD, Hart J, van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoetic stem cell transplantation (alloHCT). J Clin Oncol. 2008 May 20; 26(15_suppl):7042. PMID: 27949605.
      Citations:    
    206. Smith SM, Pro B, Cisneros A, Smith S, Stiff P, Lester E, Modi S, Dancey JE, Vokes EE, van Besien K. Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes. J Clin Oncol. 2008 May 20; 26(15_suppl):8514. PMID: 27950972.
      Citations:    
    207. Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7. PMID: 18297531.
      Citations: 2     Fields:    Translation:Humans
    208. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, Burns LJ, Cairo MS, Goldstein SC, Hale GA, Inwards DJ, Lemaistre CF, Maharaj D, Marks DI, Schouten HC, Slavin S, Vose JM, Lazarus HM, van Besien K, Freytes CO. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008 Feb; 14(2):236-45. PMID: 18215784; PMCID: PMC2531158.
      Citations: 54     Fields:    Translation:Humans
    209. Kang JA, Zhou Y, Weis TL, Liu H, Ulaszek J, Satgurunathan N, Zhou L, van Besien K, Crispino J, Verma A, Low PS, Wickrema A. Osteopontin regulates actin cytoskeleton and contributes to cell proliferation in primary erythroblasts. J Biol Chem. 2008 Mar 14; 283(11):6997-7006. PMID: 18174176; PMCID: PMC3385928.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    210. van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma. 2008; 49 Suppl 1:52-8. PMID: 18821433.
      Citations: 12     Fields:    Translation:Humans
    211. Kline J, Subbiah S, Lazarus HM, van Besien K. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant. 2008 Mar; 41(6):505-13. PMID: 18026144.
      Citations: 18     Fields:    Translation:HumansAnimals
    212. Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, Rich E, Smith SM, Zimmerman T, Zhang Y, Huo D, Larson R, van Besien K. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32. PMID: 17846595.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    213. Hill BT, Kondapalli L, Artz A, Smith S, Rich E, Godley L, Odenike O, Pursell KJ, Larson RA, Stock W, van Besien K. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma. 2007 Sep; 48(9):1799-805. PMID: 17786717.
      Citations: 6     Fields:    Translation:Humans
    214. Michaelis L, Lin S, Joseph L, Artz AS, Kline J, Pollyea D, Stock W, Rich E, Collins-Jones D, Casey B, Del Cerro P, van Besien K. Chimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplant. 2007 Jul; 40(2):181. PMID: 17502895.
      Citations:    Fields:    Translation:Humans
    215. Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP, Cancer Leukemia Group B. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007 Jun; 18(6):1071-9. PMID: 17426059.
      Citations: 103     Fields:    Translation:HumansCTClinical Trials
    216. Gordon MK, Kraus M, van Besien K. Interdigitating dendritic cell tumors in two patients exposed to topical calcineurin inhibitors. Leuk Lymphoma. 2007 Apr; 48(4):816-8. PMID: 17454644.
      Citations: 2     Fields:    Translation:HumansCells
    217. Samara MA, Brennan JM, Van Besien K, Larson RA. Cardiac tamponade in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2007 Apr; 48(4):829-32. PMID: 17454648.
      Citations: 3     Fields:    Translation:Humans
    218. van Besien K, Schouten H. Follicular lymphoma: a historical overview. Leuk Lymphoma. 2007 Feb; 48(2):232-43. PMID: 17325883.
      Citations: 3     Fields:    Translation:Humans
    219. Margolin KA, van Besien K, Peace DJ. An introduction to foundation and industry-sponsored research: practical and ethical considerations. Hematology Am Soc Hematol Educ Program. 2007; 498-503. PMID: 18024671.
      Citations: 2     Fields:    
    220. Kline J, van Besien K, Nathanson J, Noffsinger A, Artz A. Severe intestinal graft-versus-host disease following autologous stem cell transplantation. Bone Marrow Transplant. 2006 Sep; 38(5):391-2. PMID: 16915228.
      Citations: 1     Fields:    Translation:Humans
    221. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, Zimmerman T, Smith S, Godley L, Thirman M, Daugherty C, Extermann M, Larson R, van Besien K. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64. PMID: 16920562.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    222. van Besien K. Standardizing chronic graft-versus-host disease. Future Oncol. 2006 Aug; 2(4):459-62. PMID: 16922612.
      Citations: 1     Fields:    Translation:Humans
    223. van Besien K. Toxicity of high dose BCNU: how much is too much? Leuk Lymphoma. 2006 Aug; 47(8):1447-8. PMID: 16966249.
      Citations:    Fields:    Translation:Humans
    224. Danaher EH, Ferrans C, Verlen E, Ravandi F, van Besien K, Gelms J, Dieterle N. Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant. Oncol Nurs Forum. 2006 May 03; 33(3):614-24. PMID: 16676017.
      Citations: 45     Fields:    Translation:Humans
    225. Villano JL, Collins CA, Manasanch EE, Ramaprasad C, van Besien K. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol. 2006 May; 7(5):436-8. PMID: 16648049.
      Citations: 20     Fields:    Translation:Humans
    226. Navarro WH, Loberiza FR, Bajorunaite R, van Besien K, Vose JM, Lazarus HM, Rizzo JD. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 May; 12(5):541-51. PMID: 16635789.
      Citations: 33     Fields:    Translation:Humans
    227. Van Besien K. The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev. 2006 Sep; 20(5):235-44. PMID: 16513231.
      Citations: 5     Fields:    Translation:Humans
    228. Artz AS, Kocherginsky M, Van Besien K. Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation. Br J Haematol. 2006 Mar; 132(6):747-54. PMID: 16487176.
      Citations: 2     Fields:    Translation:Humans
    229. Kline J, Pollyea DA, Stock W, Artz A, Rich E, Godley L, Zimmerman T, Thompson K, Pursell K, Larson RA, van Besien K. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006 Feb; 37(3):307-10. PMID: 16400339.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    230. Schwake CJ, Eapen M, Lee SJ, Giralt SA, Navarro WH, Rizzo JD, van Besien K, Loberiza FR, Freytes CO. Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities. Biol Blood Marrow Transplant. 2005 Dec; 11(12):988-98. PMID: 16338621.
      Citations: 9     Fields:    Translation:Humans
    231. van Besien K, Deeg HJ. Hematopoietic stem cell transplantation for myelofibrosis. Semin Oncol. 2005 Aug; 32(4):414-21. PMID: 16202687.
      Citations: 2     Fields:    Translation:Humans
    232. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, Jones D, Del Cerro P, Bennett D, Casey B, Odenike O, Thirman M, Daugherty C, Wickrema A, Zimmerman T, Larson RA, Stock W. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38. PMID: 16009946.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    233. van Besien K, Smith S, Lazarus HM. Therapeutic options for patients with Hodgkin's disease and non-Hodgkin's lymphoma who relapse after autologous transplant. Curr Treat Options Oncol. 2005 Jul; 6(4):279-87. PMID: 15967081.
      Citations:    Fields:    Translation:Humans
    234. Smith SM, Pro B, van Besien K, Conner K, Karrison T, Wong S, Stiff P, Vokes E. A phase II study of Epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin's lymphomas. J Clin Oncol. 2005 Jun; 23(16_suppl):6625. PMID: 27944284.
      Citations:    
    235. Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA, van Besien K. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005 May; 35(10):965-70. PMID: 15806131.
      Citations: 21     Fields:    Translation:Humans
    236. Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res. 2005 Feb 15; 65(4):1570-6. PMID: 15735047.
      Citations: 43     Fields:    Translation:HumansCells
    237. Scarpace SL, Hahn T, Roy H, Brown K, Paplham P, Chanan-Khan A, van Besien K, McCarthy PL. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma. 2005 Feb; 46(2):239-42. PMID: 15621807.
      Citations: 17     Fields:    Translation:Humans
    238. Artz AS, Van Besien K, Zimmerman T, Gajewski TF, Rini BI, Hu HS, Stadler WM, Vogelzang NJ. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 2005 Feb; 35(3):253-60. PMID: 15543195.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    239. Van Besien K. Autologous and allogeneic stem cell transplantation in follicular lymphoma. Transfus Apher Sci. 2005 Feb; 32(1):45-53. PMID: 15737873.
      Citations: 1     Fields:    Translation:Humans
    240. van Besien K, Artz A, Stock W. Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? Leukemia. 2005 Jan; 19(1):31-3. PMID: 15526015.
      Citations: 4     Fields:    Translation:Humans
    241. Tse WW, Lazarus HM, Van Besien K. Stem cell transplantation in follicular lymphoma: progress at last? Bone Marrow Transplant. 2004 Dec; 34(11):929-38. PMID: 15489883.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    242. Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, Gale RP, Horowitz MM, Klumpp TR, Martino R, McCarthy PL, Molina A, Pavlovsky S, Pecora AL, Serna DS, Tsai T, Zhang MJ, Vose JM, Lazarus HM, van Besien K, Lymphoma Working Committee of the International Bone Marrow Transplant Registry, Freytes CO. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood. 2004 Dec 01; 104(12):3797-803. PMID: 15280203.
      Citations: 31     Fields:    Translation:Humans
    243. Van Besien K, Mehra R, Wadehra N, Stock W, Khouri I, Giralt S, Devine S, Wickrema A, Peace D, Sosman J, Gajewski J, Champlin R. Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2004 Jun; 10(6):386-94. PMID: 15148492.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    244. Van Besien K, Smith S, Anastasi J, Larson R, Thirman M, Odenike T, Stock W. Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood. 2004 Jun 01; 103(11):4373-4. PMID: 15155474.
      Citations: 2     Fields:    Translation:HumansCells
    245. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23. PMID: 15048145.
      Citations: 13     Fields:    Translation:Humans
    246. Winter JN, Gascoyne RD, Van Besien K. Low-grade lymphoma. Hematology Am Soc Hematol Educ Program. 2004; 203-20. PMID: 15561684.
      Citations: 3     Fields:    Translation:Humans
    247. Bierman PJ, Sweetenham JW, Loberiza FR, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, van Besien K, Vose JM, Horowitz M, Goldstone A, Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Gro. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003 Oct 15; 21(20):3744-53. PMID: 12963703.
      Citations: 33     Fields:    Translation:Humans
    248. Baron BW, van Besien K, Hoffman PC, Kohn OF, Rossof AH, Baron JM. Thrombotic thrombocytopenic purpura after cephalosporin administration: a possible relationship. Transfusion. 2003 Sep; 43(9):1317-21. PMID: 12919436.
      Citations: 2     Fields:    Translation:Humans
    249. Van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Hoffman R, Sossman J. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Sep; 32(5):471-6. PMID: 12942092.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    250. van Besien K, Loberiza FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ, Freytes CO, Gibson J, Horowitz MM, Inwards DJ, Marks DI, Martino R, Maziarz RT, Molina A, Pavlovsky S, Pecora AL, Schouten HC, Shea TC, Lazarus HM, Rizzo JD, Vose JM. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003 Nov 15; 102(10):3521-9. PMID: 12893748.
      Citations: 74     Fields:    Translation:Humans
    251. van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Cheung T, Vijayakumar S, Hoffman R, Sosman J. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Jul; 32(1):9-13. PMID: 12815472.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    252. Verma A, Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, van Besien K. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Bone Marrow Transplant. 2003 May; 31(9):813-6. PMID: 12732890.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    253. de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Mar 01; 97(5):1242-7. PMID: 12599231.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    254. Ravandi F, van Besien K. Clinical activity of arsenic trioxide in Burkitt-like lymphoma. Leukemia. 2003 Jan; 17(1):271-2. PMID: 12529694.
      Citations: 6     Fields:    Translation:Humans
    255. Levine JE, Harris RE, Loberiza FR, Armitage JO, Vose JM, Van Besien K, Lazarus HM, Horowitz MM, Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J, Goldstein SC, Laughlin MJ, Lister J, Marks DI, Maziarz RT, Miller AM, Milone GA, Pavlovsky S, Pecora AL, Rizzo JD, Schiller G, Schouten HC, Zhang MJ, Lymphoma Study Writing Committee, International Bone Marrow Transplant Registry and Autologous Blood. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2003 Apr 01; 101(7):2476-82. PMID: 12456505.
      Citations: 33     Fields:    Translation:Humans
    256. G-Amlak M, Uddin S, Mahmud D, Damacela I, Lavelle D, Ahmed M, van Besien K, Wickrema A. Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochem Biophys Res Commun. 2002 Oct 04; 297(4):760-4. PMID: 12359217.
      Citations: 12     Fields:    Translation:HumansCells
    257. Verma A, Deb DK, Sassano A, Kambhampati S, Wickrema A, Uddin S, Mohindru M, Van Besien K, Platanias LC. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol. 2002 Jun 15; 168(12):5984-8. PMID: 12055203.
      Citations: 38     Fields:    Translation:HumansCells
    258. Devine SM, Jahagirdar B, van Besien K. Reduced duration of cytopenias following melphalan conditioning and autografting for multiple myeloma. Blood. 2002 Jun 01; 99(11):4251-2; author reply 4252. PMID: 12043699.
      Citations:    Fields:    Translation:Humans
    259. Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W, Maynard V, Jessop E, Peace D, Huml M, Thomason D, Chen YH, van Besien K. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002 Mar 15; 99(6):2255-8. PMID: 11877308.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    260. Smith SM, Grinblatt D, van Besien K. Autologous and allogeneic transplantation for aggressive NHL. Cytotherapy. 2002; 4(3):223-40. PMID: 12194719.
      Citations: 4     Fields:    Translation:Humans
    261. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I, Huh YO, Giralt S, Braunschweig I, van Besien K, Champlin R. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001 Sep 15; 98(6):1695-700. PMID: 11535499.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    262. van Besien K, Koshy M, Anderson-Shaw L, Talishy N, Dorn L, Devine S, Yassine M, Kodish E. Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions. Bone Marrow Transplant. 2001 Sep; 28(6):545-9. PMID: 11607766.
      Citations: 20     Fields:    Translation:Humans
    263. Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D, Wickrema A, Yassine M, Amin K, Thomason D, Chen YH, Devine H, Maningo M, van Besien K. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplant. 2001 Sep; 28(6):557-62. PMID: 11607768.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    264. van Besien K, Keralavarma B, Devine S, Stock W. Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia. 2001 Sep; 15(9):1317-25. PMID: 11516091.
      Citations: 4     Fields:    Translation:Humans
    265. Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol. 2001 Aug; 67(4):227-33. PMID: 11443634.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    266. van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol. 2001 Mar 15; 19(6):1855-64. PMID: 11251018.
      Citations: 22     Fields:    Translation:Humans
    267. Sosman JA, Stiff P, Moss SM, Sorokin P, Martone B, Bayer R, van Besien K, Devine S, Stock W, Peace D, Chen Y, Long C, Gustin D, Viana M, Hoffman R. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. J Clin Oncol. 2001 Feb 01; 19(3):634-44. PMID: 11157013.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    268. Lazarus HM, Loberiza FR, Zhang MJ, Armitage JO, Ballen KK, Bashey A, Bolwell BJ, Burns LJ, Freytes CO, Gale RP, Gibson J, Herzig RH, LeMaistre CF, Marks D, Mason J, Miller AM, Milone GA, Pavlovsky S, Reece DE, Rizzo JD, van Besien K, Vose JM, Horowitz MM. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant. 2001 Feb; 27(4):387-96. PMID: 11313668.
      Citations: 30     Fields:    Translation:Humans
    269. van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, Giralt S, Mehra R, Andersson B, Gajewski J, Champlin R, Cabanillas F. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant. 2001 Feb; 27(4):397-404. PMID: 11313669.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    270. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, Pavlovsky S, Keating A, Yanes B, van Besien K, Armitage JO, Horowitz MM, Autologous Blood and Marrow Transplant Registry Lymphoma Working Committee. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001 Jan 15; 19(2):406-13. PMID: 11208832.
      Citations: 46     Fields:    Translation:Humans
    271. de Lima M, van Besien K, Gajewski J, Khouri I, Andersson B, Korbling M, Champlin R, Giralt S. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant. 2000 Aug; 26(3):333-8. PMID: 10967575.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    272. van Besien K, Bartholomew A, Stock W, Peace D, Devine S, Sher D, Sosman J, Chen YH, Koshy M, Hoffman R. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant. 2000 Aug; 26(4):445-9. PMID: 10982293.
      Citations: 22     Fields:    Translation:Humans
    273. van Besien K, Champlin IK, McCarthy P. Allogeneic transplantation for low-grade lymphoma: long-term follow-up. J Clin Oncol. 2000 Feb; 18(3):702-3. PMID: 10653889.
      Citations: 1     Fields:    Translation:Humans
    274. Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, Khouri IF, Folloder J, Ueno NT, Mehra R, Ippoliti C, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Anderlini P, Andersson BS, Champlin R. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant. 2000; 6(2A):190-7. PMID: 10816027.
      Citations: 1     Fields:    Translation:Humans
    275. Donato ML, Champlin RE, Van Besien KW, Korbling M, Cabanillas F, Anderlini P, Gajewski JG, Lauppe J, Durett A, Andersson B, Giralt S, Khouri I, Hagemeister F, Romaguera JE, Sarris A, McLaughlin P, Younes A, Ippoliti C, Blamble DA, Hester J, Gee A, Rodriguez MA. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Oct; 35(3-4):317-24. PMID: 10706456.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    276. Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Giralt S, Gajewski J, Fischer H, Donato M, Cleary K, Claxton D, Chan KW, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R, Körbling M. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999 Oct; 24(7):763-8. PMID: 10516680.
      Citations: 21     Fields:    Translation:Humans
    277. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, Huh YO, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R, Körbling M. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999 Aug 15; 94(4):1465-70. PMID: 10438735.
      Citations: 43     Fields:    Translation:Humans
    278. Warkentin D, Ippoliti C, Bruton J, Van Besien K, Champlin R. Toxicity of single daily dose gentamicin in stem cell transplantation. Bone Marrow Transplant. 1999 Jul; 24(1):57-61. PMID: 10435736.
      Citations: 1     Fields:    Translation:Humans
    279. Przepiorka D, Khouri I, Thall P, Mehra R, Lee MS, Ippoliti C, Giralt S, Gajewski J, van Besien K, Andersson B, Deisseroth AB, Champlin R, Körbling M. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant. 1999 May; 23(10):977-81. PMID: 10373061.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    280. Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R, Körbling M. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32. PMID: 10416001.
      Citations: 14     Fields:    Translation:Humans
    281. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ, Gajewski JL, Gale RP, Keating A, Klein JP, Miller CB, Phillips GL, Reece DE, Sobocinski KA, van Besien K, Horowitz MM. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999 Feb; 17(2):534-45. PMID: 10080597.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    282. Margolin KA, Van Besien K, Wright C, Niland J, Champlin R, Fung HC, Kashyap A, Molina A, Nademanee AP, O'Donnell MR, Parker P, Smith E, Spielberger R, Somlo G, Snyder D, Stein A, Woo D, Thomas M, Sniecinski I, Forman SJ. Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. Biol Blood Marrow Transplant. 1999; 5(1):36-45. PMID: 10232739.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    283. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, Chaekal OK, Gale RP, Klein JP, Lazarus HM, McCarthy PL, Raemaekers JM, Reiffers J, Phillips GL, Schattenberg AV, Verdonck LF, Vose JM, Horowitz MM. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998 Sep 01; 92(5):1832-6. PMID: 9716615.
      Citations: 28     Fields:    Translation:Humans
    284. Ueno NT, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE, Rondón G, Körbling M. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998 Mar; 16(3):986-93. PMID: 9508181.
      Citations: 21     Fields:    Translation:Humans
    285. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998 Feb 15; 91(4):1178-84. PMID: 9454747.
      Citations: 62     Fields:    Translation:Humans
    286. Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I, Claxton D, de Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F, van Besien K. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol. 1998 Jan; 16(1):63-9. PMID: 9440724.
      Citations: 11     Fields:    Translation:Humans
    287. van Besien K, Margolin K, Champlin R, Forman S. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. Cancer J Sci Am. 1997 Dec; 3 Suppl 1:S54-8. PMID: 9457395.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    288. Ippoliti C, Morgan A, Warkentin D, van Besien K, Mehra R, Khouri I, Giralt S, Gajewski J, Champlin R, Andersson B, Przepiorka D. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant. 1997 Sep; 20(6):491-5. PMID: 9313883.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    289. van Besien K, Thall P, Korbling M, Pugh WC, Khouri I, Mehra R, Giralt S, Anderlini P, Amin K, Mirza N, Seong D, Gajewski J, Hester J, Andersson B, Cabanillas F, Champlin R, Przepiorka D. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant. 1997 Aug; 3(3):150-6. PMID: 9310192.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    290. Giralt S, Estey E, Albitar M, van Besien K, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Keating M, Kantarjian H, Champlin R, Rondón G, Kørbling M. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15; 89(12):4531-6. PMID: 9192777.
      Citations: 158     Fields:    Translation:HumansCTClinical Trials
    291. Gajewski J, Gjertson D, Cecka M, Tonai R, Przepiorka D, Hunt L, Giralt S, Chan KW, Feig S, Territo M, Andersson B, van Besien K, Khouri I, Fischer H, Babbitt L, Ippolitti C, Schiller G, Lill M, Warkentin D, Neumann J, Petz L, Terasaki P, Champlin R. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 1997 Jun; 3(2):76-82. PMID: 9267667.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    292. van Besien K, Forman A, Champlin R. Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann Oncol. 1997 Jun; 8(6):515-24. PMID: 9261519.
      Citations: 1     Fields:    Translation:Humans
    293. Khouri IF, Przepiorka D, van Besien K, O'Brien S, Palmer JL, Lerner S, Mehra RC, Vriesendorp HM, Andersson BS, Giralt S, Keating MJ, Champlin RE, Körbling M. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May; 97(2):466-73. PMID: 9163617.
      Citations: 9     Fields:    Translation:Humans
    294. van Besien KW, de Lima M, Giralt SA, Moore DF, Khouri IF, Mehra R, Andersson BS, Dyer C, Cleary K, Przepiorka D, Gajewski JL, Champlin RE, Rondón G. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant. 1997 May; 19(10):977-82. PMID: 9169641.
      Citations: 28     Fields:    Translation:Humans
    295. van Besien K, Verschraegen C, Mehra R, Giralt S, Kudelka AP, Edwards CL, Piamsonboom S, Termrungruanglert W, Champlin R, Kavanagh JJ. Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue. Gynecol Oncol. 1997 May; 65(2):366-9. PMID: 9159354.
      Citations: 6     Fields:    Translation:Humans
    296. Giralt S, Pereira M, Van Besien K, Mehra R, Champlin R, Andreeff M, Rondón G. Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization. Leuk Lymphoma. 1997 May; 25(5-6):463-7. PMID: 9250816.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    297. Przepiorka D, Anderlini P, Ippoliti C, Khouri I, Fietz T, Thall P, Mehra R, Giralt S, Gajewski J, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, Körbling M. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997 Mar; 19(5):455-60. PMID: 9052911.
      Citations: 3     Fields:    Translation:Humans
    298. Giralt S, Davis M, O'Brien S, van Besien K, Champlin R, de Vos D, Kantarjian H. Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia. 1997 Mar; 11 Suppl 1:S32-4. PMID: 9130690.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    299. Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, Gajewski J, Andersson B, Khouri I, Przepiorka D, von Wolff B, Delasalle K, Korbling M, Seong D, Alexanian R, Champlin R. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol. 1997 Feb; 15(2):667-73. PMID: 9053492.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    300. Piamsomboon S, Kudelka AP, Termrungruanglert W, Van Besien K, Edwards CL, Lifshitz S, Schomer DF, Champlin R, Mante RP, Kavanagh JJ, Verschraegen CF. Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): first report and review of literature. Eur J Gynaecol Oncol. 1997; 18(6):453-6. PMID: 9443008.
      Citations: 2     Fields:    Translation:Humans
    301. Verschraegen CF, van Besien KW, Dignani C, Hester JP, Andersson BS, Anaissie E. Invasive Aspergillus sinusitis during bone marrow transplantation. Scand J Infect Dis. 1997; 29(4):436-8. PMID: 9360268.
      Citations: 3     Fields:    Translation:HumansCells
    302. de Lima M, van Besien KW, Giralt SA, Khouri IF, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Korbling M, Champlin RE. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997 Jan; 19(2):121-7. PMID: 9116608.
      Citations: 8     Fields:    Translation:Humans
    303. Przepiorka D, Ippoliti C, Khouri I, Anderlini P, Mehra R, Giralt S, Gajewski J, Fritsche H, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, Korbling M. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation. 1996 Dec 27; 62(12):1806-10. PMID: 8990368.
      Citations: 1     Fields:    Translation:Humans
    304. van Besien K, Przepiorka D, Mehra R, Giralt S, Khouri I, Gajewski J, Andersson B, Champlin R. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol. 1996 Nov; 14(11):3036-42. PMID: 8918502.
      Citations: 6     Fields:    Translation:Humans
    305. Chan KW, Anderlini P, Seong D, Durett A, Langlinais A, Przepiorka D, Gajewski J, Miller P, Sundberg J, Alilaen P, Bojko P, Mirza N, Claxton D, van Besien K, Khouri I, Andersson B, Mehra R, Champlin R, Körbling M. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors. Bone Marrow Transplant. 1996 Nov; 18(5):885-90. PMID: 8932841.
      Citations: 1     Fields:    Translation:HumansCells
    306. van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF, Moon Y, Williams P, Andersson BS, Przepiorka D, McCarthy PL, Gajewski JL, Deisseroth AB, Cabanillas FF, Champlin R. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med. 1996 Mar; 100(3):299-307. PMID: 8629675.
      Citations: 12     Fields:    Translation:Humans
    307. van Besien K, Giralt S. Autologous bone marrow transplantation for leukemia and lymphoma. Cancer Treat Res. 1996; 84:207-59. PMID: 8724632.
      Citations:    Fields:    Translation:Humans
    308. Giralt SA, van Besien K. Treatment of relapse after allogeneic bone marrow transplantation. Cancer Treat Res. 1996; 84:279-90. PMID: 8724634.
      Citations: 2     Fields:    Translation:Humans
    309. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R, Rondón G, Körbling M. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995 Dec 01; 86(11):4337-43. PMID: 7492795.
      Citations: 33     Fields:    Translation:HumansCells
    310. Ippoliti C, Przepiorka D, Mehra R, Neumann J, Wood J, Claxton D, Gajewski J, Khouri I, van Besien K, Andersson B, et al. Intravesicular carboprost for the treatment of hemorrhagic cystitis after marrow transplantation. Urology. 1995 Dec; 46(6):811-5. PMID: 7502421.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    311. Huh YO, Durett A, Mirza N, Miller P, Engel H, Anderlini P, van Besien K, Andreeff M, Przepiorka D, Deisseroth AB, Champlin RE, Körbling M. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995 Oct 01; 86(7):2842-8. PMID: 7545476.
      Citations: 18     Fields:    Translation:HumansCells
    312. Giralt S, O'Brien S, Talpaz M, Van Besien K, Chan KW, Andersson B, Mehra R, Khouri I, Estey E, Rondón G, et al. Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation. Cytokines Mol Ther. 1995 Jun; 1(2):115-22. PMID: 9384668.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    313. van Besien KW, Khouri IF, Giralt SA, McCarthy P, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Bellare N, Nath R, et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol. 1995 May; 13(5):1096-102. PMID: 7738615.
      Citations: 6     Fields:    Translation:Humans
    314. van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I, et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant. 1995 Apr; 15(4):549-55. PMID: 7655380.
      Citations: 6     Fields:    Translation:Humans
    315. Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB, Körbling M, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995 Mar 15; 85(6):1659-65. PMID: 7888684.
      Citations: 30     Fields:    Translation:HumansCells
    316. van Besien K, Demuynck H, Lemaistre CF, Bogaerts MA, Champlin R. High-dose melphalan allows durable engraftment of allogeneic bone marrow. Bone Marrow Transplant. 1995 Feb; 15(2):321-3. PMID: 7773226.
      Citations: 2     Fields:    Translation:Humans
    317. Giralt SA, LeMaistre CF, Vriesendorp HM, Andersson BS, Dimopoulos M, Gajewski J, Van Besien K, Mehra R, Przepiorka D, Khouri I, et al. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol. 1994 Sep; 12(9):1923-30. PMID: 8083714.
      Citations: 9     Fields:    Translation:Humans
    318. Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, Andersson BS, van Besien KW, Mehra RC, Giralt SA, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol. 1994 Apr; 12(4):748-58. PMID: 8151318.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    319. Przepiorka D, Ippoliti C, Panina A, Goodrich J, Giralt S, van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna M, et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant. 1994 Apr; 13(4):461-4. PMID: 8019472.
      Citations: 1     Fields:    Translation:HumansCells
    320. Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra R, van Besien K, Delasalle KB, Reading C, et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood. 1993 Oct 15; 82(8):2324-8. PMID: 8104539.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    321. Van Besien K, Tricot G, Hoffman R. Relapsing polychondritis: a paraneoplastic syndrome associated with myelodysplastic syndromes. Am J Hematol. 1992 May; 40(1):47-50. PMID: 1340759.
      Citations: 8     Fields:    Translation:Humans
    322. Straneva JE, van Besien KW, Derigs G, Hoffman R. Is interleukin 6 the physiological regulator of thrombopoiesis? Exp Hematol. 1992 Jan; 20(1):47-50. PMID: 1577093.
      Citations: 2     Fields:    Translation:HumansCells
    323. van Besien K, Tricot G, Golichowski A, Padilla L, Hoffman R. Pregnancy-associated aplastic anemia--report of 3 cases. Eur J Haematol. 1991 Oct; 47(4):253-6. PMID: 1954983.
      Citations: 2     Fields:    Translation:Humans
    324. van Besien K, Hoffman R, Golichowski A. Pregnancy associated with lupus anticoagulant and heparin induced thrombocytopenia: management with a low molecular weight heparinoid. Thromb Res. 1991 Apr; 62(1-2):23-9. PMID: 1712988.
      Citations: 1     Fields:    Translation:Humans
    325. Srour EF, Brandt JE, Briddell RA, Leemhuis T, van Besien K, Hoffman R. Human CD34+ HLA-DR- bone marrow cells contain progenitor cells capable of self-renewal, multilineage differentiation, and long-term in vitro hematopoiesis. Blood Cells. 1991; 17(2):287-95. PMID: 1717081.
      Citations: 20     Fields:    Translation:HumansCells
    326. Srivastava A, Bruno E, Briddell R, Cooper R, Srivastava C, van Besien K, Hoffman R. Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. Blood. 1990 Nov 15; 76(10):1997-2004. PMID: 2146978.
      Citations: 29     Fields:    Translation:HumansCells
    327. Dayton MA, van Besien K, Tricot G, Hoffman R. Preleukemic state preceding adult acute lymphoblastic leukemia. Am J Med. 1990 Nov; 89(5):657-62. PMID: 2239985.
      Citations:    Fields:    Translation:Humans
    328. Brandt J, Srour EF, van Besien K, Briddell RA, Hoffman R. Cytokine-dependent long-term culture of highly enriched precursors of hematopoietic progenitor cells from human bone marrow. J Clin Invest. 1990 Sep; 86(3):932-41. PMID: 1697607; PMCID: PMC296813.
      Citations: 13     Fields:    Translation:HumansCells
    329. van Besien K, Nichols CR, Tricot G, Langefeld C, Miller ME, Akard L, English DK, Graves VL, Cheerva A, McCarthy LJ, et al. Characteristics of engraftment after repeated autologous bone marrow transplantation. Exp Hematol. 1990 Aug; 18(7):785-8. PMID: 2165911.
      Citations:    Fields:    Translation:HumansCells
    330. Brandt JE, Srour EF, van Besien K, Hoffman R. Characterization of human hematopoietic stem cells. Prog Clin Biol Res. 1990; 352:29-36. PMID: 2205867.
      Citations:    Fields:    Translation:HumansCells
    331. Hoffman R, Briddell RA, van Besien K, Srour EF, Guscar T, Hudson NW, Ganser A. Acquired cyclic amegakaryocytic thrombocytopenia associated with an immunoglobulin blocking the action of granulocyte-macrophage colony-stimulating factor. N Engl J Med. 1989 Jul 13; 321(2):97-102. PMID: 2659998.
      Citations: 9     Fields:    Translation:HumansCells
    332. Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R, Wolff SN, et al. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989 Jul; 7(7):932-9. PMID: 2544687.
      Citations: 50     Fields:    Translation:Humans
    333. Van Hootegem P, Van Besien K, Broeckaert L, Rutgeerts P, Fevery J. Endoscopic sclerotherapy of esophageal varices. Long-term follow-up, recurrence, and survival. J Clin Gastroenterol. 1988 Aug; 10(4):368-72. PMID: 3262137.
      Citations: 3     Fields:    Translation:Humans
    Van Besien's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (759)
    Explore
    _
    Co-Authors (45)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _